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Abstract 
Background: Oxacillin and cloxacillin are the most frequently used penicillins for the treatment of severe methicillin‑
susceptible Staphylococcus aureus infections in intensive care units (ICUs), especially endocarditis. International recom‑
mendations do not suggest any adaptation of the dosage in case of renal impairment. We wanted to assess the risk 
factors for overdosing in ICU and the related observed side effects.
Methods: All patients with a therapeutic drug monitoring of oxa‑ or cloxacillin between 2008 and 2014 were 
included. The target range of trough concentration for total antibiotic activity was considered to be 20–50 mg/L. Data 
concerning the infection, the given treatment, the renal function, and the attributed side effects of overdosing were 
collected. A logistic regression model was used to compute the measured trough concentrations.
Results: Sixty‑two patients were included in this study. We found a median trough plasma concentration of 
134.3 mg/L (IQR 65.3–201 mg/L). Ten patients (16.1%) reached the target concentration; all other patients (83.9%) 
were overdosed. Eleven patients (17.7%) experienced neurological side effects attributed to a high antibiotic concen‑
tration, i.e. persistent coma and delirium. When adjusted on the dosage used, the risk of overdosing was significantly 
associated with a creatinine clearance <10 mL/min (with or without hemodialysis).
Conclusion: With the suggested dose of 12 g/day for cloxacillin treatment in case of endocarditis and severe infec‑
tions occurring in ICU, 83.9% of patients are largely overdosed. Considering the observed side effects, doses should be 
accurately monitored and reduced, particularly when renal replacement therapy is needed.
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Background
Beta-lactams are first-choice antibiotics for most infec-
tions in intensive care units [1]. Oxacillin and cloxacillin 
are the most frequently used penicillins for the treatment 
of methicillin-susceptible Staphylococcus aureus (MSSA) 
infections. Since this bacterium is responsible for more 
than one quarter of all endocarditis, in both a nosocomial 
and community context [2–4], these antibiotics stand at 
the forefront of the latest European Society of Cardiol-
ogy guidelines [5]. Given such criteria as safety of use and 
low level of toxicity, as opposed to the well-known effect 
of aminoglycosides or vancomycin [6], the therapeu-
tic drug monitoring of these molecules has never been 
widespread.
As all penicillins, oxacillin and cloxacillin are time-
dependent antibiotics. For severe infections, the target 
is to obtain 100% of time above the minimum inhibitory 
concentration (MIC), or even 4×  MIC to avoid emer-
gence of resistances [7]. To reach this concentration, 
high doses and prolonged infusion are recommended 
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in ICU patients with an increased distribution volume 
[8, 9] and glomerular hyperfiltration [10]. The dosage 
of 12  g/day (200  mg/kg/day as specified only for chil-
dren) is recommended by consensus conferences to 
treat severe infections, without mentioning any spe-
cific attention in case of renal failure [5, 11]. Recently, 
the French Health Authority (Haute Autorité de Santé 
or HAS) has suggested to reduce the dose by 50% when 
creatinine clearance falls below 30 mL/min [12], leading 
to subsequent modifications of the medication approval.
There is also a lack of data in the literature concern-
ing a possible accumulation in the event of prolonged 
use, particularly in case of endocarditis or endovascular 
infections. Thus, ICU patients are potentially exposed to 
severe complications, essentially neurological [13, 14], 
hepatic [15, 16], and renal [17–19].
The aim of our study was to analyze oxacillin and clox-
acillin plasma concentrations in critical care patients 
in order to identify risk factors for overdosing, its fre-
quency, and the observed adverse effects.
Methods
Clinical and biological data
All patients with oxacillin or cloxacillin therapeutic 
monitoring performed between 2008 and 2012 in the 
intensive care units of Hôpital Bichat, Paris, France, 
were retrospectively included in the study. Patients 
from 2012 to 2014 were included prospectively after 
72 h of administration of treatment in our ICU. We col-
lected clinical characteristics, medical history, charac-
teristics of the infectious process, date of the infection, 
date of oxacillin start, and given dose. Creatinine clear-
ance has been systematically measured with the follow-
ing formula:
renal failure, i.e. when creatinine clearance was inferior 
to 30 mL/min. Usually, in cases of endocarditis or end-
ovascular infections, 2  g were administered four times 
a day instead of six, the latter being the recommended 
dosage for the treatment of endocarditis. Finally, 
Sequential Organ Failure Assessment (SOFA) score [20] 
and Simplified Acute Physiology Score (SAPS) II [21] 
were assessed at the time of admission and drug moni-
toring. The Naranjo Adverse Drug Reaction Probability 
Scale was used to assess whether the observed adverse 
effects were due to the drug or not, via a score termed 
definite, probable, possible, or doubtful [22].
Oxacillin and cloxacillin assays
The concentration of cloxacillin or oxacillin in serum was 
measured by microbiological assay with Bacillus subtilis as 
assay organism, which is resistant to third-generation ceph-
alosporins, macrolides, quinolones, fusidic acid, rifampin, 
fosfomycin, and cyclines. Standard solutions of differ-
ent concentrations of the tested antibiotic were prepared. 
Hundred milligrams of cellulose phosphate was added to 
patients’ serum in order to adsorb aminoglycosides. After 
30  min and a centrifugation, the collected supernatant 
did not contain aminoglycoside anymore. A volume of 25 
microliters of each standard solution containing cloxacillin 
or oxacillin and patient’s sample were poured on sterile fil-
ter papers of 6 mm placed on plates made with a Bacillus 
subtilis broth. Each measure was repeated three times. The 
plates were refrigerated at 4  °C to facilitate the diffusion 
of the antibiotic and then incubated at 37 °C for 18 h. The 
inhibition zone diameters were measured, and the concen-
trations of the test specimens were derived from the stand-
ard line constructed from the standard solution.
Pharmacokinetics and pharmacodynamics (PK/PD) target
According to the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST), the MIC threshold to 
determine the strain sensitivity is 0.5 mg/L for oxacillin 
and 2  mg/L for cloxacillin [23]. Until now, the optimal 
plasma concentration target in order to achieve the best 
cure rate remains undefined, but as oxa- and cloxacillin 
are time-dependent antibiotics, a time of 100% above the 
minimum inhibitory concentration (MIC) was consid-
ered to be optimal for efficacy. Considering that oxa- and 
cloxacillin are highly bound to albumin and that their 
unbound fraction—i.e. the available fraction for antibi-
otic efficacy—in healthy patients is known to be 10%, we 
defined a target range of total antibiotic concentration of 
20–50 mg/L to reach the 100% T > MIC.
Ccreatinine in urine( mmol/L)× volume of urine for the last 24 h( mL)× 1000
Ccreatinine in plasma (µmol/L)× 1440
When data were missing, glomerular filtration rate was 
estimated with MDRD formula. We checked that the 
plasma concentrations matched the trough blood con-
centration before a new injection and identified the time 
lag between the plasma concentration measure and the 
latest hemodialysis session, when appropriate. We also 
addressed issues relating to hepatic function, serum 
protein level and serum albumin level when avail-
able. We estimated the unbound fraction of antibiotics 
according to the serum albumin or protein level. Other 
associated antimicrobials were also recorded, notably 
aminoglycosides. The day of ICU admission was called 
Day-O, the beginning of oxa- or cloxacillin treatment 
T-Day, and the day of plasma concentration measure 
D-Day. The dosing of antibiotics was reduced in case of 
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Estimation of the unbound fraction of antibiotics
Considering that oxa- and cloxacillin are highly bound to 
albumin (up to 90%) [24], we assumed that the unbound 
fraction increased in hypoproteinemic patients. In the 
study by Ulldemolins et  al. [25] involving flucloxacillin, 
the relationship between percentage protein binding and 
plasma albumin levels was found to be linear, with r2 val-
ues of 0.5691. We estimated the increase in the unbound 
fraction with the percentage of decrease in albumine-
mia, extrapolated from the ratio albumin/serum protein 
when albumin was not available. In our hospital labora-
tory, hypoalbuminemia was defined as a value inferior to 
32 g/L.
Statistical analysis
Clinical characteristics and therapeutic drug monitoring 
were reported as median IQR or n (%) for quantitative 
and qualitative variable, respectively. Variables associated 
with a plasma concentration superior to the target range 
of 20–50 mg/L were computed using a logistic regression 
model. Antibiotic dose (mg/kg) was forced in the models, 
providing that the dose was adapted to renal function by 
the clinician. A p value of 0.05 was considered significant. 
All the statistical analyses were performed using SAS 9.4 
and R softwares.
Results
Sixty-two patients were included in this study, represent-
ing 94 drug monitorings. For patients included prospec-
tively after 2012, a flowchart is available in Additional 
file  1: Figure S1. Cloxacillin was the most frequently 
used molecule in our work, as it was administered to 56 
patients (90.3%), whereas oxacillin was given to the six 
others (9.7%).
Data concerning the first plasma concentration meas-
ure performed for each patient are summarized in 
Table  1. Twenty-three patients (37% of the cases) were 
mechanically ventilated with a P/F ratio under 200, 37 
(59.7%) had a creatinine clearance of less than 10 mL/min 
requiring renal replacement therapy for 33 (53%) of them, 
and 30 (48%) required catecholamines. Data to calculate 
creatinine clearance were missing for nine patients; with 
MDRD formula, one of them had an estimated creati-
nine clearance between 10 and 30 mL/Min, and the eight 
others above 30  mL/min. The ICU mortality was 41.9% 
(n = 26). For 96% of the patients, the involved bacterium 
was Staphylococcus aureus; two patients suffered from 
Coagulase-negative Staphylococcus- and Staphylococcus 
epidermidis-related infections.
We defined three different categories of infections: 
endocarditis (n =  33, 53.2%), other endovascular infec-
tions (15 patients, 24.2%), and a third group including 
all the extravascular infections—particularly pneumonia 
Table 1 Patients characteristics
Sex, number (%)
 F 16 (25.8)
 M 46 (74.2)
Age, years, median (IQR) 63 [54; 71]
Weight at Day 0, kg, median (IQR) 80 [73; 92]
BMI, median (IQR) 27.8 [24.3; 32.5]
Cause of admission, number (%)
 Sepsis 38 (61.3)
 Acute respiratory failure 9 (14.5)
 Coma 9 (14.5)
 Cardiogenic shock 6 (9.7)
 Renal replacement therapy 6 (9.7)
 Post‑surgery 5 (8.1)
 Other 4 (6.5)
Type of ICU admission, number (%)
 Medical 33 (53.2)
 Surgical 29 (46.8)
Charlson comorbidity score, median (IQR) 2 [0; 4]
Comorbidities, number (%)
 None 22 (35.5)
 Diabetes mellitus 24 (38.7)
 Chronic heart failure 16 (25.8)
 Chronic renal disease 12 (19.4)
 Hemodialysis dependent 8 (12.9)
 COPD 8 (12.9)
 Cirrhosis 2 (3.2)
Creatinine base level, µmol/L, median [IQR] 93 [74; 117]
SAPS II, median [IQR] 56 [40; 73]
SOFA score at Day 0, median [IQR] 8 [6, 11]
Type of infection, number (%)
 Endocarditis of native valve 30 (48.4)
 Endocarditis of prosthetic valve 3 (4.8)
 Bacteremia without endocarditis 9 (14.5)
 Infusion catheter infection 6 (9.7)
 Pneumonia 9 (14.5)
 Mediastinitis 4 (6.5)
 Other 1 (1.6)
Bacteremia, number (%) 56 (90.3)
Weight on D‑Day, kg, median [IQR] 88.5 [75.5; 98]
Daily dosing per kg, mg/kg, median [IQR] 105.5 [75; 150]
Plasma concentration, mg/L, median [IQR] 134.3 [65.3; 201]
Serum protein level, g/L 56 [51; 64]
Albuminemia, g/L 20 [13, 21]
Side effects attributed to overdose
 Delirium 8 (12.9)
 Persistent coma 3 (4.8)
 Acute renal failure 5 (8.1)
SOFA score on D‑Day, median [IQR] 8 [6, 13]
Creatinine clearance on D‑Day, mL/min
 <10 or hemodialysis 37 (59.7)
 10–30 7 (11.3)
 >30 18 (29.0)
Type of hemodialysis technique
 CVVHD 4 (12.5)
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and mediastinitis, representing the remaining 14 patients 
(22.6%). Bacteremia occurred in fifty-six patients (90.3%). 
Only two patients underwent extracorporeal life support.
Fifty-two patients (83.9%) included in this study had 
a high plasma concentration in oxacillin or cloxacil-
lin (Fig. 1). Only ten of them reached the trough plasma 
concentration target of 20 to 50 mg/L. Using a percent-
age of 10% to estimate the unbound fraction of oxa- or 
cloxacillin, all patients would have had a trough unbound 
fraction concentration superior or equal to the maximum 
MIC for oxa- or cloxacillin sensitivity, i.e. 2 mg/L. As the 
median ratio albumin/total serum protein level was 33% 
for the patients with available data, we used the meas-
ured or estimated albumin level in our population to esti-
mate the median unbound fraction of oxa- or cloxacillin, 
which was 18 mg/L.
Twenty-nine patients had at least another antibiotic 
administered in the last 24  h before dosage: rifampicin 
(n = 14), ofloxacin (n = 5), vancomycin (n = 4), piperacil-
lin/tazobactam (n = 3), clindamycin (n = 2), spiramycin 
(n = 1), cefotaxime (n = 1), erythromycin (n = 1), imi-
penem (n = 1), levofloxacin (n = 1), daptomycin (n = 1), 
ciprofloxacin (n = 1), and cotrimoxazole (n = 1).
We identified an median time lag of 6  days [4; 11] 
between the starting date of the treatment and plasma 
concentration measure. The analysis of trough concen-
tration level on the basis of this time lag did not high-
light any variation (Fig.  2). The total dosing of oxa- or 
cloxacillin was 12 g for 23 patients (37.1%), 8–10 g for 17 
patients (27.5%), 6 g or less for 21 patients (33.9%). Only 
one patient received a dose superior to 12 g, i.e. 16 g. The 
dose reduction in case of renal failure was statistically 
significant (Table 2). 
Through a univariate data analysis on the basis of a 
logistic regression model, we identified the variables 
potentially affecting the plasma concentration, i.e. the 
infected site (endocarditis) and the presence of a bacte-
remia, the D-Day SOFA score, and a creatinine clearance 
below 10 mL/min on D-Day. Univariate analysis is shown 
in detail in Table 3. A multivariate analysis revealed that 
the variables remaining significant were the dose-to-
weight ratio (i.e. the weight on admission, p = 0.049) and 
the creatinine clearance level at the time of plasma con-
centration measure (p = 0.0067).
Fourteen patients (22.6%) experienced side effects 
attributed to an overdosing in oxa- or cloxacillin, as 
measured by the microbiological method (i.e. represent-
ing the total antimicrobial activity in plasma). Eleven 
(17.7%) presented with neurological symptoms, i.e. per-
sistent coma for three patients and delirium for eight 
patients (12.9%). The median trough concentration of the 
antibiotic for those patients was 165 mg/L, with a mini-
mum at 97  mg/L, and a maximum at 302  mg/L. Head 
CT scans showed no abnormalities in four patients, and 
formerly known strokes for 5. An electroencephalo-
gram (EEG) was performed for six of the 11 patients and 
showed the presence of reactivity but a slow background 
activity. Taking into account the other medications Fig. 1 Distribution of antibiotic blood concentrations
Fig. 2 Relationship between antibiotic serum level and day of blood 
sample
Table 2 Daily dosing and creatinine clearance
* This analysis has been performed with a Mann Whitney test
Creatinine clearance (mL/min)
<10 10–30 >30 p*
n = 37 n = 7 n = 18
Dosing per 24 h, g, 
median [IQR]
8 [6–10] 6 [6–12] 12 [10–12] 0.002
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administered to patients (i.e. sedatives and other anti-
biotics), the Naranjo score for the six patients with an 
EEG was 6, and 5 for the five other ones, which classi-
fied the observed neurological events as ‘probably’ due 
to oxacillin overdosing. Comparing the patients with 
and without neurological side effects, we found no sta-
tistically significant differences in terms of age, weight, 
renal function, length of stay (respectively, 64 vs 42 days, 
p = 0.14), or mortality at day 90 (41.7 vs 52%, p = 0.52), 
but the median duration of treatment was longer (32.5 vs 
14 days, p = 0.03). Neurological evolution was favorable 
after reduction in treatment dose in all patients.
Discussion
Our study is the first one to thoroughly evaluate oxacillin 
dosage in the context of extremely severe infections. We 
found a plasma trough concentration of oxa- or cloxacil-
lin above the target level for a large proportion of patients 
and a quarter of them experienced side effects that were 
attributed to the high antibiotic concentration. The lat-
est international recommendations for the treatment of 
endocarditis provide for a cloxacillin or oxacillin dose of 
12 g/j for an adult, without reference to weight or renal 
function [5]. It is interesting to note that these recom-
mendations have been slightly modified in the past 
40  years, although the relevant patients population has 
changed; the average age of patients, in particular, has 
tremendously increased and concomitantly the propor-
tion of patients with impaired renal function [26]. In the 
literature, the data related to a modification of the dosing 
of these antibiotics in case of impaired renal function are 
weak and contradictory. In the book ‘The use of antibiot-
ics’ by Kucer, it is mentioned that the dose should nor-
mally be reduced in case of impaired renal function, and 
especially if very high intravenous doses are used [27]. 
Other recommendations point in the same direction, 
notably from the HAS in 2012, whereby a reduction in 
the doses by half is proposed in case of renal impairment 
and creatinine clearance below 30 mL/min [12]. However, 
none of these recommendations rely on pharmokinetics 
data published in the literature. There are very few dif-
ferences between oxa- and cloxacillin PK/PD parameters 
Table 3 Statistical analysis—univariate analysis
Trough concentration ≤50 Trough concentration >50 mg/L OR IC 95% p value
n = 10 n = 52 – –
Age 59.5 [53; 67] 63 [54; 72] 1.026 [0.98; 1.08] 0.29
BMI 26.1 [22.8; 29.1] 28.4 [24.6; 32.8] 1.110 [0.96; 1.29] 0.17
Indication for ICU admission
 Sepsis 4 (40) 34 (65.4) 2.833 [0.71; 11.35] 0.14
Creatinine base level 91 [70; 96] 94 [75; 120] 1.001 [1; 1.01] 0.69
Hemodialysis dependence 1 (10) 7 (13.5) 1.400 [0.15; 12.81] 0.77
SAPS II 52 [36; 73] 56 [40; 71] 1.002 [0.97; 1.04] 0.92
SOFA score on Day 0 7 [4, 10] 9 [6, 11] 1.151 [0.93; 1.42] 0.20
SOFA score on Day 0 without renal failure 7 [3, 9] 7 [5, 8] 1.068 [0.86; 1.33] 0.55
Type of infection
 Infective endocarditis 2 (20) 31 (59.6) 8.611 [1.42; 52.09] 0.02
 Other intravascular infection 3 (30) 12 (23.1) 2.222 [0.42; 11.83] 0.35
 Other infection 5 (50) 9 (17.3) 1.000 0.06
Bacteremia 7 (70) 49 (94.2) 7.001 [1.17; 41.75] 0.03
Daily dosing per kg, mg/kg 101.3 [75.9; 111.1] 108.1 [75; 150] 1.007 [0.99; 1.02] 0.43
Time lag between treatment initiation and D‑Day, d, 
median [IQR]
5 [3, 7] 6.5 [4; 12.5] 1.099 [0.95; 1.27] 0.19
SOFA on D‑Day 7 [4, 8] 9 [6, 14] 1.256 [1.01; 1.56] 0.04
SOFA on D‑Day without renal failure 5 [3, 7] 6.5 [4, 10] 1.140 [0.93; 1.4] 0.22
SOFA > 7 on D‑Day without renal failure 2 (20) 23 (44.2) 3.172 [0.61; 16.41] 0.17
Creatinine clearance on D‑Day, mL/min
 <10 or RRT 2 (20) 35 (67.3) 11.136 [2.01; 61.65] <0.01
 10–30 1 (10) 6 (11.5) 3.818 [0.38; 38.83] 0.26
 >30 7 (70) 11 (21.2) 1.000 0.02
Aminoglycosides 4 (40) 27 (51.9) 1.620 [0.41; 6.42] 0.49
Serum protein level on D‑Day, g/L 0.944 [0.88; 1.01] 0.11
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[27]. As said before, both are highly bound to albumin, 
i.e. more than 90%, and distribution of the two drugs in 
the body after parenteral administration is similar. After 
IV administration, 70–80% of the injected dose of cloxa-
cillin is eliminated by urinary route in 6  h, in an active 
form, and the rest by the biliary tract, also in active form; 
the biliary elimination is more marked for oxacillin. No 
data are available in the literature regarding potential dif-
ferences between their metabolites’ toxicity. A first phar-
macological study published by Nauta et al. [28] assessed 
pharmacokinetics of orally administered cloxacillin in 
11 healthy subjects and 11 patients on chronic intermit-
tent hemodialysis. They found a cloxacillin half-life (T1/2) 
3 times higher in hemodialysis patients than in healthy 
ones, but a lower absorption. Thus, they recommended 
using the same dosing in anuric patients, but this did 
not concern intravenous administration. Thijssen and 
Wolters [29] observed a prolonged half-life of antibacte-
rial activity in plasma of patients treated with flucloxacil-
lin and presenting with renal failure, mainly because of 
the accumulation of an active metabolite, hydroxyflu-
cloxacillin. This metabolite has a longer half-life than flu-
cloxacillin, and a lower plasma clearance by a non-renal 
route. Although some accumulation of the hydroxyflu-
cloxacillin metabolite was observed, they recommended 
no adjustment of the flucloxacillin dose in severe renal 
impairment, because of a low metabolite toxicity.
All of these data did not concern ICU patients. PK/PD 
of beta-lactams in an intensive care context is very com-
plex and often unpredictable [8]. Although an increase 
in cardiac output, glomerular filtration, and distribution 
volume would make the case for a higher dosing, the 
emergence of an acute renal failure exposes the patient 
to the risk of an overdosing [30]. Moreover, the target to 
reach a 100% T > MIC often leads to increase treatment 
doses.
Verdier et  al. [31] analyzed plasma concentrations of 
oxacillin in 57 patients, half of them being treated for 
endocarditis. Twenty-nine patients had an altered cre-
atinine clearance below 60  mL/min, as estimated with 
the Cockcroft and Gault formula, but very few of them 
had a clearance of less than 10 mL/min; furthermore, no 
renal replacement therapy was mentioned. However, they 
showed that plasma concentrations were higher in case 
of altered renal function and highlighted the interindi-
vidual variability of concentrations after administration 
of high doses of cloxacillin. Visser et  al. [32] suggested 
the existence of variations of a saturable mechanism of 
tubular excretion, explaining the accumulation of anti-
biotics during treatments with continuous infusions 
even in patients with normal renal function. In this latter 
study, the authors tried to predict plasma concentration 
of cloxacillin administered in continuous infusions with 
an equation including creatinine clearance and weight; 
patients with a creatinine clearance inferior to 10  mL/
min had to be excluded of the study, because the predic-
tion remained unreliable.
 Several studies reported neurological side effects of 
these molecules [33, 34]. Malone et  al. [13] reported 
convulsions with a concentration of 270 mg/L. Delirium 
increases the duration of ICU stay and mechanical ven-
tilation and is associated with a poor outcome, includ-
ing subsequent cognitive decline and mortality [35, 
36]. We found in our study 17.7% of patients suffering 
from neurological adverse effects that were attributed 
by the clinician in charge to an overdosing in oxa- or 
cloxacillin. Patients were receiving several medications, 
including sedatives, at the same time, and retrospec-
tive design makes it difficult to establish the responsi-
bility of the overdosing. Nevertheless, other frequent 
causes of delirium as pain, new cerebral lesions or sepsis 
were ruled out, and neurological recovery was observed 
after stopping or adapting treatment dose. The Naranjo 
scores classified those adverse events as ‘probably’ due 
to the antibiotic.
Considering the high proportion of patients with renal 
replacement therapy included in our study, it appears 
that this population is particularly at risk of overdosing 
and must be accurately monitored.
Our study had several limitations. Data were collected 
retrospectively for 25 patients (40.3%) before 2012, but 
there was no difference in the dosage of administered 
antibiotics between the two study periods. Moreover, 
the day retained for collecting the blood samples was 
not the same for all patients; even if the dosing was made 
prospectively after 2012, blood samples could only be 
collected and analyzed in the laboratory on week  days. 
Nonetheless, statistical analysis did not reveal any differ-
ence in the median trough concentration based upon the 
day of the measure. Finally, before 2012, the reason for 
assessing oxa- or cloxacillin concentration was not men-
tioned; we could suppose clinicians suspected an over-
dosing because of observed side effects. However, among 
those 25 patients, only three were reported to have expe-
rienced adverse effects due to overdosing.
It has also to be noted that the oxa- and cloxacillin 
assay used in our study represents a total antibiotic activ-
ity of oxa- and cloxacillin, thus including all active metab-
olites, but does not evaluate its unbound fraction. This 
method is the same as the one used by Nauta and Mat-
tie [37] and Bulger et  al. [38] in former studies. Verdier 
et al. [31] used high-performance liquid chromatography 
(HPLC) to measure antibiotic concentrations that could 
explain their lower proportion of overdosing in normo-
renal patients. Whether we should take into account the 
presence of the active metabolites or not to determine 
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the optimal trough concentration target to reach is not 
known. Indeed, it is interesting to notice that the MIC 
of oxacillin or cloxacillin metabolites for Staphylococcus 
aureus is equivalent to that of the parent compounds, i.e. 
0.5–1.2 mg/L, in the study by Thijssen and Mattie [39]. In 
the same study, they observed that the amount of active 
metabolites represented 40–50% of the plasmatic penicil-
lin activity in patients on chronic intermittent hemodi-
alysis. Thus, it appears that the microbiological method 
may more accurately estimate the total antimicrobial 
activity in the plasma. Whether or not the metabolites 
are as effective as the parent compound to treat infec-
tions in vivo is not known, since their distribution may be 
different. However, in the case of endocarditis or endo-
vascular infections, this might not influence the outcome 
of therapy.
As compared to microbiological method, HPLC dos-
ing method has also the advantage to give clinicians a 
result more rapidly. However, in our center, we were able 
to obtain a trough concentration of oxa- or cloxacillin in 
48  h, which was considered to be a reasonable delay to 
adapt treatment dosing.
Due to the retrospective design of our study, we were 
not able to measure the unbound fraction of oxa- or 
cloxacillin in our patients’ plasma. Ulldemolins et al. [25] 
showed that the unbound fraction of flucloxacillin was 
more important in case of hypoalbuminemia, leading to 
an increased volume of distribution of the molecule and 
to a risk of underdosing. As most of our patients had a 
low serum protein level and consequently a low albu-
min concentration, we estimated that the unbound frac-
tion of oxa- or cloxacillin was also increased, compared 
to healthy patients in which it represents 10% of the total 
antibiotic concentration. If we extrapolate the unbound 
fraction increase in the same proportion of the decrease 
in albumin concentration, none of our patients would 
have had an unbound oxa- or cloxacillin trough level infe-
rior to 2 mg/L. Considering the very high concentrations 
obtained in our population with an important propor-
tion of patients with impaired renal function, the role of 
albumin in pharmacokinetics and pharmacodynamics of 
highly protein-bound antibiotics, like oxacillin, might be 
of less relevance. As suggested by Benet and Hoener [40], 
changes in plasma protein binding will usually not influ-
ence the clinical exposure of a patient to a drug, except for 
some specific cases of a drug with a high extraction ratio 
and narrow therapeutic index that is intravenously admin-
istered. Moreover, the study by Ulldemolins et al. did not 
consider the plasma concentration of non-protein-bound 
fraction of hydroxyflucloxacillin, which may play a part in 
antimicrobial efficacy, and which is estimated to be twice 
as large as that of its parent compound in previous studies 
[29].
We therefore deem it essential to monitor and adapt 
dosing of frequently used molecules in intensive care, 
including antibiotics. In order to avoid antibiotic accu-
mulation in our ICU patients, a systematic plasma con-
centration measure of oxacillin has been set in our unit. 
The efficiency of this provision has to be determined.
Through this study, we could identify the need for renal 
replacement therapy as a major risk factor for overdosing. 
In spite of a reduction in dosage in case of renal failure, it 
did not allow us to avoid overdosing in our intensive care 
population. Even if the severity of our patients’ condi-
tion may be an additional risk factor for overdosing in an 
ICU context, the proposed reduction by half of the dos-
age when the creatinine clearance is less than 30 mL/min 
is far from satisfactory. Further pharmacokinetic study is 
needed to clarify the mechanisms of this overdosing and 
to provide guidelines for dosage when facing renal func-
tion impairment.
We therefore propose to develop a systematic thera-
peutic drug monitoring for oxa- and cloxacillin in ICU, 
as could be done for aminoglycosides or vancomycin, 
in order to optimize the managing and monitoring of 
patients. Faster techniques such as HPLC have largely 
developed these last few years, allowing for a reliable 
plasma concentration measure of numerous molecules 
[41].
Nevertheless, the question concerning the efficiency 
of this dosing method to evaluate the accumulation of 
active metabolites and their potential toxicity remains 
unanswered.
Conclusions
With the proposed reduction by half of the dosage of 
oxa- and cloxacillin when the creatinine clearance is less 
than 30  mL/min, a large proportion of patients remain 
overdosed. In multivariate analysis, identified risk fac-
tors for overdosing were the dose-to-weight ratio and an 
impaired renal function. Considering the severity of the 
observed side effects, especially coma and delirium, ICU 
patients with renal failure must be accurately monitored.
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